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Hematopoietic stem cells (HSCs) can reconstitute the entire 
hematopoietic system after transplantation into hosts whose 
hematopoietic compartment has been ablated. This is clini-
cally exploited as HSC transplantation (HSCT) to treat he-
matologic disease and represents the only curative therapy for 
many disorders (Cavazzana et al., 2014; Cohen et al., 2015; 
Talano and Cairo, 2015). Unfortunately, the application of 
HSCT can be limited by a paucity of HSCs, especially in cord 
blood transplantation (Zhong et al., 2010). As such, tremen-
dous effort has been exerted to develop protocols that allow 
for the expansion of transplantable HSCs ex vivo. Strategies 
range from identifying transcriptional regulators and devel-
oping supportive stroma to identifying small molecules that 
promote expansion (Walasek et al., 2012). However, these ap-
proaches are limited by the tendency of HSCs to differentiate 
in culture and have not yet been clinically translated.
One alternative for improving HSCT is to enhance 
HSC engraftment itself. Successful HSCT requires that donor 
HSCs engage with the proper supporting niche, survive, pro-
liferate, and differentiate into mature blood lineages. These 
processes are associated with numerous stresses, including 
myelotoxic conditioning that alters the niche, ex vivo manip-
ulation of HSCs, and the requirement for supraphysiological 
hematopoietic expansion during engraftment and reconsti-
tution. Recent studies indicate that stress hematopoiesis, in-
cluding that which occurs after HSCT, is subject to distinct 
biological regulation compared with baseline hematopoiesis 
occurring in healthy individuals (Rossi et al., 2012). Further, 
the hematopoietic stem and progenitor cells (HSPCs) that 
maintain hematopoiesis after HSCT may differ from those 
that sustain native hematopoiesis (Sun et al., 2014; Busch et 
al., 2015). These differences highlight the importance of dis-
secting the cellular and molecular mechanisms that uniquely 
regulate the function of HSPCs after transplant. PGE2, shown 
to promote HSC engraftment by up-regulating homing 
pathways and enhancing self-renewal has recently been tested 
in Phase 1 clinical trials where it enhanced the long-term 
engraftment of cord blood (Hoggatt et al., 2009; Cutler et al., 
2013). Although more work is needed, this suggests that en-
hancing HSC engraftment can improve transplant outcomes. 
Understanding the mechanisms that regulate the stable re-
population of the hematopoietic compartment by HSPCs is 
paramount to developing new therapies to further improve 
Understanding the molecular regulation of hematopoietic stem and progenitor cell (HSPC) engraftment is paramount to im-
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HSCT. Thus, here we report a functional screen for novel 
regulators of HSPC engraftment and repopulation.
Prior functional screens of murine and human HSCs 
have focused on identifying genes that promote HSPC 
self-renewal and/or maintenance during ex vivo culture (Ali 
et al., 2009; Deneault et al., 2009; Boitano et al., 2010; Hope 
et al., 2010; Fares et al., 2014). In these studies, purified mu-
rine HSCs or enriched human HSPCs were transduced with 
the open reading frames of genes of interest (GOI), trans-
duced with shRNAs targeting GOI, or treated with small 
molecule libraries. Cells were then maintained ex vivo for 
5–17 d before downstream assays, which included transplan-
tation into ablated mice for a rigorous functional assessment 
of HSC numbers, in vitro colony assays, or flow cytometry for 
retention of an HSPC cell surface phenotype. In each of these 
studies, extensive ex vivo culture before downstream analysis 
precluded a direct assessment of the effect of treatment on 
HSC engraftment, as this would be difficult to separate from 
effects on HSC expansion, differentiation during culture, or 
even non–cell-autonomous effects on HSC maintenance, as 
was seen in one study (Deneault et al., 2009). In contrast, 
our goal is to identify genes critically required for the stable 
repopulation of an ablated hematopoietic system. To achieve 
this, we developed a system in which HSPCs treated with 
shRNAs are subjected to minimal ex vivo culture before 
transplantation into cohorts of ablated mice, allowing us to 
directly assess any effect of the loss of gene expression on 
HSC engraftment and hematopoietic reconstitution. Here, 
we report the identification of 17 genes whose loss perturbs 
short- and long-term HSPC repopulation: 15 genes required 
for optimal repopulation and 2 inhibitors of stable HSPC en-
graftment, as their loss enhanced HSPC repopulation. 12 of 
these genes have never before been implicated in HSPC biol-
ogy, including Foxa3 (formally known as hepatocyte nuclear 
factor 3γ or HNF-3γ). Foxa3 belongs to the Foxa subclass 
of Fox (Forkhead Box) DNA-binding factors. FOXA pro-
teins are transcriptional pioneer factors that establish com-
petence for downstream transcriptional programs (Friedman 
and Kaestner, 2006). Foxa3 has primarily been studied for its 
role in endoderm and endoderm-derived tissue development 
(Friedman and Kaestner, 2006). However, a role for Foxa3 in 
several nonendodermal lineages has recently been described 
(Behr et al., 2007; Ionescu et al., 2012; Xu et al., 2013), sug-
gesting a broader role in tissue development and function. 
Here, we further demonstrate a novel role for Foxa genes in 
HSC biology via investigation of Foxa3−/− mice.
RES ULTS
Identification of candidate genes for functional screen
The following public databases of HSC gene expression were 
interrogated to prioritize 51 gene candidates for study: He-
matopoietic Fingerprints, the Immunological Genome Proj-
ect, and StemSite (Chambers et al., 2007; Heng and Painter, 
2008; McKinney-Freeman et al., 2012). Gene candidates 
were prioritized if their expression was enriched in adult 
HSC relative to downstream progeny or earlier stages of HSC 
ontogeny. Quantitative RT-PCR (qRT-PCR) was used to in-
terrogate the expression of each prioritized gene candidate in 
cells isolated from murine BM (Fig. 1, A and B). We found 
that 44/51 GOI were expressed in lineage− BM hematopoi-
etic cells, the majority of which were highly enriched for 
expression in Lineage−Sca-1+c-Kit+ (LSK) cells relative to 
downstream progeny (Fig. 1 B).
To interrogate a role for GOI in HSC engraftment, we 
used shRNAs to disrupt their expression in LSK cells be-
fore transplantation into lethally irradiated mice. At least four 
miR-30–embedded shRNAs were designed to target each 
of the 44 GOI whose expression was validated in HSPCs. 
shRNAs were cloned into a lentiviral vector downstream 
of an MSCV promoter and upstream of a phosphoglycerate 
kinase promoter driving the fluorescent reporter mCherry 
(Fig. 1 A). Each shRNA was transduced into LSK cells and 
tested for gene knockdown by qRT-PCR. Mean transduc-
tion for these experiments was 76.7 ± 7% (Fig. 1 C). At least 
two shRNA were identified that affected >75% transcript 
knockdown in LSK cells for 41/44 GOI (Fig. 1 D and Table 
S2). Thus, these genes were further screened.
We next conducted pilot studies to assess the feasi-
bility of using highly purified HSCs (LSK CD150+CD48− 
cells) in our screen. CD45.2+ HSCs were transduced with 
control shRNAs and transplanted with an equal number of 
mock-transduced CD45.1+ HSCs into CD45.1+/CD45.2+ 
recipients. These experiments suffered from high signal/
noise incompatible with a robust screen (unpublished data). 
We determined that this high signal/noise resulted primarily 
from the technical difficulty of evenly distributing small cell 
numbers among mice in a cohort. Thus, we chose to use the 
more abundant LSK cell population for our screen. Although 
LSK cells are a mixture of HSPCs, by >16 wk after trans-
plants, we can readily assess the effect of gene knockdown on 
stable HSC repopulation. Indeed, pilot studies also revealed 
that HSCs consistently transduce with a slightly higher fre-
quency than LSK cells (Fig.  1 E). Thus, HSCs are robustly 
transduced in our system.
Functional screen for novel regulators of HSC engraftment
CD45.2+ Test LSK cells were transduced with individual shR-
NAs and then transplanted into ablated CD45.1+/CD45.2+ 
mice with an equal number of CD45.1+ mock-transduced 
Competitor LSK cells (Fig.  2  A). Cells were transplanted 
within 24 h of their isolation and transduction; i.e., there was 
no extended ex vivo culture period as in previous functional 
screens of primary HSPCs (Ali et al., 2009; Deneault et al., 
2009; Hope et al., 2010). For each transplant, an aliquot of 
transduced cells was maintained in liquid culture and an-
alyzed after 3–4 d for transduction efficiency. Mean trans-
duction for these experiments was 67.6 ± 8.5% (Fig. 2 B). 
Recipient peripheral blood (PB) was analyzed for Test versus 
Competitor contribution for >16 wk after transplant. A total 
of 781 mice were transplanted.
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Loss-of-function hits
Knockdown of 18 genes resulted in a loss of HSPC repopu-
lating potential relative to control with two independent shR-
NAs in our initial screen (Arhgef5, Cadps2, Col4a2, Crispld1, 
Emcn, Foxa3, Glis2, Gng11, Gpr56, Myct1, Nbea, P2ry14, 
Rbpms, Sox4, Stat4, Trp53bp1, Trpc6, and Zbtb20; Fig. 2 C). 
Repopulation loss was apparent 4 wk after transplant and per-
sisted for >16 wk for all GOI except Stat4 (Fig. 2 C), where 
the loss of repopulation was most dramatic >16 wk after trans-
plant. Knockdown of most of these genes did not affect the 
short-term (i.e., 14 d) maintenance of hematopoietic cells ex 
vivo (unpublished data). In contrast, knockdown of 20 GOI 
did not affect in vivo repopulating potential (Fig. 2 D). To con-
firm stable gene knockdown in our system, mice transplanted 
with LSK cells transduced with Grb10 shRNAs, a non-hit, 
were examined (Fig. 2, E–G). Both Grb10 shRNAs effected 
>95% transcript loss in LSK cells (Fig. 2 F). qRT-PCR anal-
ysis of CD45.2+ LSK cells isolated from mice transplanted 30 
wk prior with either control or Grb10 shRNA–treated cells 
revealed persistent gene knockdown in these cells (Fig. 2 G).
Figure 1. Functional screen for regulators of HSPC in vivo repopulation. (A) Screen schematic. 51 prioritized genes were assessed by qRT-PCR for 
expression in LSK cells. miR30-embedded shRNAs targeting each gene expressed in LSK cells were cloned into a lentiviral vector downstream of the MSCV 
promoter. Here, the phosphoglycerate kinase (PGK) promoter drives mCherry. (B) Heat map of qRT-PCR of GOI in LSK cells, Lineage− cells, and Lineage+ cells. 
Scale indicates gene expression relative to population expressing the highest level of each gene across each row (1 = dark red). (C) BM LSK cells transduced 
with shRNAs were assayed 3–4 d after transduction for mCherry. Each circle is an independent transduction event. (D) BM LSK cells transduced with shRNAs 
were examined 3–4 d after transduction by qRT-PCR. Each circle is an independently screened shRNA. Circles in red denote shRNAs used in the screen. 
(E) Transduction efficiency (%mCherry+) of LSK cells and HSCs (i.e., LSK CD150+CD48−) at multiple MOI 4 d after transduction.
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Figure 2. Identification of genes required for HSPC in vivo repopulation. (A) shRNAs were transduced into CD45.2+ Test LSK cells that were then 
transplanted into CD45.1+/CD45.2+ mice with an equal number of CD45.1+ mock-transduced Competitor LSK cells. Recipient PB was analyzed for >16 wk 
for CD45.2+ cells. (B) Transduction of Test LSK cells for each screen transplant. For each transplant, an aliquot of Test cells was assessed for the percentage of 
mCherry+ cells 4 d after transduction. Each circle represents an independent transduction. (C and D) Loss-of-function hits (C) and non-hits (D). Percentage 
of CD45.2 PB 4 and >16 wk after transplant of recipients of gene-specific shRNA–treated Test cells normalized to that of recipients of control shRNA–
treated Test cells. Each gene was interrogated with two independent shRNAs (labeled as a and b). (E) Percentage of CD45.2 PB of mice transplanted with 
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Knockdown of six GOI yielded a repopulating loss 
with only 1/2 shRNAs tested (Eya2, Fstl1, Gucy1a3, Msrb2, 
Rbp1, and Myct1; Fig.  2, C and D). In each case, except 
Myct1 (discussed in the next section), this loss of repopu-
lation was attributable to nonspecific toxicity of the effect-
ing shRNA (e.g., a third Gucy1a3 shRNA did not affect 
repopulation; Fig. 3 F).
Confirmation of loss-of-function screen hits
The 18 hits identified in our screen were retested to con-
firm their role as regulators of LSK cell in vivo repopulat-
ing activity. Here, to improve resolution, only vector+ Test 
LSK cells (mCherry+CD45.2+) were transplanted into ab-
lated mice (Fig. 3 A). Cells were sorted and transplanted 44 h 
after transduction, along with an equal number of CD45.1+ 
mock-transduced and mock-sorted Competitor LSK cells. A 
series of pilot studies revealed that a minimum of 40 h was 
required after transduction to visualize and isolate vector+ LSK 
cells by flow cytometry (Fig. 3 B). Here, we also retested five 
genes that scored as non-hits (Fstl1, Gucy1a3, Rbp1, Smarca2, 
and Zfp521; Fig. 2 D). Smarca2 and Zfp521 were retested be-
cause transduction efficiency was low in our initial screen for 
these genes or their shRNAs did not yield a complete gene 
knockdown, resulting in a possible false negative (Fig.  3, C 
and D). Fstl1, Gucy1a3, and Rbp1 were non-hits whose two 
shRNAs yielded disparate outcomes in our initial screen, ne-
cessitating a more thorough analysis. A total of 527 mice were 
transplanted in these experiments.
15 loss-of-function hits retested were confirmed as 
requirements for optimal HSPC repopulation (Fig.  3 E). 
Repopulation loss was more dramatic in these experiments 
relative to our initial screen, likely because of greater reso-
lution resulting from transplantation of only vector+ cells. 
Three genes that initially scored as non-hits were scored 
as hits when retested: Fstl1, Smarca2, and Zfp521. As 
mentioned, the transduction efficiencies for Smarca2 and 
Zfp521 were low in our initial screen (Fig.  3  C), likely 
resulting in a false negative in those experiments. As both 
transduction and gene knockdown for Fstl1 were high in 
our initial screen (Fig.  2 B and not depicted), it appears 
that transplantation of only vector+ cells is necessary to 
clearly resolve a repopulating loss with both Fstl1 shRNAs. 
Alternatively, the prolonged culture in these experiments 
might exact additional stress on the cells, resulting in a loss 
of in vivo repopulation not apparent in our original screen. 
Six initial hits did not affect repopulating potential when 
retested: Col4a2, Gng11, Rbpms, Trp53bp1, Trpc6, and 
Zbtb20 (Fig. 3 F). As only one Zbtb20 shRNA was tested 
in our initial screen, two additional Zbtb20 shRNAs were 
tested in our confirmation experiments (Fig.  3  F). Only 
the original Zbtb20 shRNA mediated a loss of repopula-
tion, suggesting that this shRNA likely had off-target ef-
fects. Once again, Stat4 was the only hit that displayed a 
significant increase in repopulating loss between 4 and >16 
wk after transplant (Fig. 3 E), suggesting that Stat4 regu-
lates the long-term repopulating potential of HSCs, rather 
than their early engraftment. The distribution of T, B, or 
myeloid cells in the mCherry+CD45.2+ compartment of 
recipients was only significantly perturbed in recipients of 
Cadps2 and Foxa3 shRNA–treated cells (Fig. 3 G). Loss of 
Cadps2 resulted in a significant expansion of B cells and a 
concomitant loss of T cells, suggesting that lymphoid pro-
genitor function might be perturbed. Loss of Foxa3 per-
turbed the myeloid compartment (Fig. 3 G).
In sum, via our two-pronged screening approach, we 
rigorously identified 15 genes required for LSK cell in vivo 
repopulating activity: Arhgef5, Cadps2, Crispld1, Emcn, 
Foxa3, Fstl1, Glis2, Gpr56, Myct1, Nbea, P2ry14, Smarca2, 
Sox4, Stat4, and Zfp521 (Fig. 3 E). These GOI regulate a 
diverse array of cellular processes, including epigenetics, ad-
hesion and migration, vesicle trafficking and cell surface re-
ceptor turnover, and the extracellular matrix.
Gain-of-function hits: loss of Gprasp2 and Armcx1 
promotes HSPC repopulation
Loss of Gprasp2 appeared to favor LSK cell in vivo repop-
ulating activity in our study. Here, mCherry+CD45.2+ was 
positively selectedover time in the PB of 17/20 recipients 
of Gprasp2 shRNA–transduced LSK cells compared with 
only 2/9 recipients of control cells (Fig.  4  A). Similarly, 
loss of Armcx1 also appeared to enhance HSPC repopula-
tion (Fig. 4 Bi). As only mCherry+ cells were transplanted 
in these experiments, it was not possible to monitor for 
mCherry selection. However, although not statistically sig-
nificant, 7/11 recipients of Armcx1 shRNA–transduced 
Test HSPCs showed moderately enhanced chimerism >16 
wk after transplant relative to controls (Fig. 4 B, i). To rigor-
ously assess whether loss of Armcx1 or Gprasp2 enhanced 
LSK cell in vivo repopulating activity, mCherry+CD45.2+ 
Test LSK cells (transduced with either gene-specific or 
control shRNAs) were transplanted 1:4 with CD45.1+ 
mock-transduced and mock-sorted Competitor LSK cells, 
thus putting the Test cells at a significant repopulating dis-
advantage relative to Competitor. Here, loss of Armcx1 
Grb10 shRNA or control shRNA–transduced Test cells. Knockdown of Grb10 had no effect on LSK cell repopulating activity. (F) LSK cells transduced with 
control or Grb10 shRNAs were examined 4 d after transduction for the percentage of mCherry+ cells. (G) 30 wk after transplant, CD45.2+ LSK cells were 
isolated from the BM of individual mice transplanted with CD45.2+ LSK cells transduced with either control or Grb10 shRNAs. These cells were examined 
by qRT-PCR for Grb10 transcript levels. For C–F, the mean of five recipient mice is presented, and error bars represent SD. For C, a one-sample Student’s t 
test was performed testing the null hypothesis that the normalized measurements = 1. P-values are two-sided. §, P < 0.1; *, P < 0.05; **, P < 0.005; ***, P < 
0.0001. Only p-values calculated >16 wk after transplant are shown.
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and Gprasp2 enhanced the repopulating potential of Test 
LSK cells in the majority of transplanted mice (Fig. 4 B, 
ii). This result was true for multiple independent shRNAs 
tested for each gene. Loss of Armcx1 and Gprasp2 did not 
appear to perturb any specific hematopoietic PB lineages 
(Fig. 4 C). Loss of the gene Leprel2 also appeared to en-
hance repopulation in both our initial screen and after re-
testing (P = 0.02; Fig. 4 B, i; and not depicted). However, 
when Leprel2 was reexamined in a 1:4 Test versus Com-
petitor transplant, enhanced repopulation was no longer 
apparent (Fig. 4 B, ii).
In summary, loss of Gprasp2 and Armcx1 enhanced 
LSK cell repopulating activity, suggesting that these genes may 
negatively impact HSPC engraftment. Interestingly, Gprasp2 
and Armcx1 belong to the same family of G-protein coupled 
receptor associated sorting proteins (GASP), strongly impli-
cating this gene family in the negative regulation of HSPC 
repopulating potential (Abu-Helo and Simonin, 2010).
Figure 3. Validation of loss-of-function hits identifies 15 genes required for robust HSPC repopulating activity. (A) For retesting hits, 
mCherry+CD45.2+ Test HSPCs (LSK cells) transduced with either control or gene-specific shRNAs were transplanted into CD45.1+/CD45.2+ mice with 
an equal number of CD45.1+ mock-transduced and mock-sorted Competitor HSPCs. Recipient PB was analyzed for >16 wk for CD45.2+ cells. (B) 
Representative flow cytometry analysis of LSK cell and HSCs (i.e., LSK CD150+CD48−) 40 h after transduction with control shRNA lentiviral vector. 
Samples were examined for the frequency of mCherry+ cells. (C) Transduction efficiency (percentage of mCherry+ cells) of Test LSK cells transduced 
with Smarca2 and Zfp521 shRNAs in primary screen. (D) Knockdown efficacy of shRNAs targeting Smarca2, Zfp521, and Zbtb20 assessed by qRT-PCR 
3–4 d after transduction of LSK cells. (E) Verified loss-of-function hits. A one sample Student’s t test was performed testing the null hypothesis that 
the normalized measurements = 1. P-values are two-sided. §, P < 0.1; *, P < 0.05; **, P < 0.005; ***, P < 0.0001. Only p-values calculated >16 wk after 
transplant are shown. (F) Functional screen non-hits. In E and F, each gene was interrogated with at least two independent shRNAs (labeled as a, b, 
or c) and the percentage of CD45.2 PB at 4 and >16 wk after transplant of recipients of gene-specific shRNA–treated Test cells normalized to that of 
recipients of control shRNA–treated Test cells is shown. (G) Distribution of T, B, and myeloid PB lineages in mCherry+CD45.2+ compartment of genes 
that scored as hits after retesting >16 wk after transplant. In E–G, each bar is the average of at least four recipient mice, and error bars represent SD. 
In G, asterisks denote a statistically significant difference in distribution of at least one lineage relative to control for both shRNAs tested (P < 0.05). 
P-values were calculated using the exact Wilcoxon Mann-Whitney test. ND, not determined.
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Interrogation of the cellular mechanism of gene loss on 
HSPC repopulating potential
To illuminate the cellular mechanisms of gene knockdown on 
HSPCs, LSK cells transduced with control or gene-specific 
shRNAs were assayed for CFU potential, cell cycle, and apop-
tosis (Fig. 5, A and B; and Fig. S1). We also examined CD45.2+ 
chimerism in the BM of recipients of gene-deficient CD45.2+ 
LSK cells >16 wk after transplant (Fig. 5 C).
LSK cells lacking Nbea and Glis2 displayed an increase 
in CFU-GEMM potential (P = 0.046 and 0.07, respectively; 
Figure 4. Functional screen identifies 
Gprasp2 and Armcx1 as negative regula-
tors of HSPC repopulation. (A) Gprasp2 or 
control shRNAs were transduced into CD45.2+ 
LSK cells that were then transplanted into 
CD45.1+/CD45.2+ mice with an equal number 
of CD45.1+ mock-transduced Competitor LSK 
cells. Recipient PB was analyzed for 20 wk. 
Percentage of mCherry+ CD45.2+ PB of recip-
ients of Gprasp2 shRNA–treated cells normal-
ized to the percentage of mCherry+CD45.2+ 
PB of recipients of control shRNA–treated 
cells. Gprasp2 was tested in two independent 
experiments with three shRNAs (a–c). Cu-
mulative results shown for both experiments 
(n ≥ 5 at all time points). (B) Validation of 
gain-of-function hits (Gprasp2, Armcx1, and 
Leprel2). Gprasp2, Leprel2, Armcx1, or con-
trol shRNAs were transduced into CD45.2+ 
HSPCs. mCherry+ HSPCs were resorted 40  h 
after transfection and transplanted either 1:1 
or 1:4 with CD45.1+ mock-transduced and 
mock-sorted Competitor HSPCs into CD45.1+/
CD45.2+ mice. Data shown is the percentage of 
CD45.2+ recipient PB of gene-specific shRNA–
treated cells normalized to that of recipients 
of control shRNA–treated cells at >16 wk after 
transplant for 1:1 (i) or 1:4 (ii) transplants. 
Armcx1 was examined with three shRNAs 
(a–c) in a single (i) and three (ii) independent 
experiments. Gprasp2 was interrogated with 
two shRNAs (b and d) in a single experiment 
(ii). Leprel2 was examined with two shRNAs (a 
and b) in a single experiment for both i and ii. 
(C) Distribution of T, B, and myeloid PB lineages 
in mCherry+CD45.2+ compartment of gain-of-
function hits from >16 wk after transplant. 
In A and C, each value is the mean of n ≥ 5 
mice; error bars represent SD. *, P < 0.04; **, 
P < 0.008. P-values were calculated via exact 
Wilcoxon Mann-Whitney test. 
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Fig. 5 A). This correlated with a loss of CD45.2+ chimerism 
downstream of HSCs or multipotent progenitors (MPPs) in 
recipients of LSK cells deficient in these genes (Fig.  5  C). 
These data suggest a block in differentiation at the HSC or 
MPP stage, resulting in an accumulation of CFU-GEMM. 
Glis2-deficient LSK cells also displayed elevated apoptosis ex 
vivo (P = 0.08; Fig. 5 B), suggesting that this block in differ-
entiation exists in concert with reduced progenitor survival 
downstream of HSCs and MPPs.
Knockdown of Stat4, Zfp521, and Foxa3 also resulted 
in an enhanced loss of CD45.2+ chimerism downstream 
of HSCs in transplanted mice (Fig.  5  C ). Knockdown of 
Zfp521 in LSK cells ex vivo resulted in a slight expansion of 
CFU-G/M/GM at the expense of CFU-GEMM (P = 0.08) 
and an ∼50% loss of apoptotic cells, although CFU-G/M/
GM expansion and loss of apoptosis did not score as statisti-
cally significant here (Fig. 5, A and B). These data suggest that 
CFU-GEMM lacking Zfp521 differentiate rapidly to com-
mitted progenitors that display enhanced survival ex vivo, but 
fail to establish robust chimerism in vivo.
Arhgef5 and Emcn knockdown caused a significant loss 
in total CFU from LSK cells (P = 0.027; P = 0.035, respec-
tively), whereas Fstl1 knockdown resulted in a dramatic, but 
only marginally significant, loss in CFU (P = 0.096; Fig. 5 A). 
This correlated with a loss of CD45.2+ chimerism across all 
BM compartments in recipients of LSK cells deficient in these 
genes, except for Fstl1, for whom BM chimerism was not de-
termined (Fig. 5 C). As Emcn-deficient LSK cells did not dis-
Figure 5. Functional analysis of screen hits. (A) 500 mCherry+ LSK cells transduced with control or gene-specific shRNAs were assayed for CFU potential 
5 d after transduction. Values are the mean of two to three independent experiments normalized to control ± SE. (B) Cell cycle status of the mCherry+ LSK 
cell compartment, the frequency of mCherry+ LSK cells, and apoptosis of mCherry+ LSK cells was analyzed 5 d after transduction with control or gene-specific 
shRNAs. Values are the mean of two to three independent experiments normalized to control ± SE. For A and B, a one-sample Student’s t test was performed 
testing the null hypothesis that the normalized measurements = 1. P-values are two-sided. §, P < 0.1; *, P < 0.05; **, P < 0.005. (C) Heat map summarizing mean 
percentage of CD45.2+ (Test cell–derived) HSC, MPP, CMP, CLP, GMP, and MEP in recipients >16 wk after transplant. Values are normalized to control recipients 
(i.e., 1 = yellow). Higher chimerism relative to control = darker green; lower chimerism relative to control = darker red. ND, not determined.
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play significant perturbations in cell cycle or apoptosis ex vivo, 
loss of in vivo repopulating activity may result from perturbed 
niche interactions after transplant effecting survival, differenti-
ation, or proliferation. However, Arhgef5-deficient LSK cells 
displayed about a 40% expansion of cells in G1 ex vivo, relative 
to control (P = 0.089), which was commensurate with a modest 
reduction of cells in both G0 and G2–S–M (P > 0.05 for both). 
Thus, perturbations in cell cycle progression may contribute 
to the repopulating defect of Arhgef5-deficient LSK cells. In 
addition to a dramatic loss in total CFU, Fstl1-deficient cells 
displayed a rapid loss of the LSK cell surface phenotype during 
culture (P = 0.079), suggesting accelerated differentiation com-
mensurate with a loss of stem and progenitor cell potential. 
Knockdown of Cadps2 in CD45.2+ LSK cells also resulted 
in a loss of CD45.2+ chimerism across all BM compartments 
after transplant (Fig. 5 C). This correlated with perturbations 
in the frequency of select CFU: a marginally significant, albeit 
modest, loss of CFU-E (P = 0.057) and a marginally signifi-
cant increase in CFU-G/M/GM (P = 0.06) was apparent after 
knockdown of this gene (Fig. 5 A).
In contrast, recipients of Armcx1 and Gprasp2 shRNA–
treated cells displayed enhanced CD45.2+ chimerism in all 
HSPC compartments, correlating with enhanced PB chime-
rism (Fig. 4 B and Fig. 5 C). LSK cells treated with Gprasp2 
shRNAs displayed significantly enhanced survival ex vivo and 
a twofold expansion of cells in G0, commensurate with a loss 
of cells in G2–S–M (P = 0.002). Thus, enhanced survival and a 
slow-growing phenotype may contribute to enhanced in vivo 
repopulation here, as observed in Runx1 mutants whose HSCs 
also display a repopulating advantage (Cai et al., 2015). In con-
trast, knockdown of Armcx1 in LSK cells ex vivo had no signif-
icant effect on CFU formation, cell cycle, or apoptosis (Fig. 5, 
A and B), suggesting that enhanced repopulation after knock-
down of Armcx1 may result from specific in vivo interactions.
Foxa3−/− HSCs display reduced in vitro and in vivo 
hematopoietic potential
Our screen identified Foxa3 as a putative novel regulator of 
LSK cell in vivo repopulating activity (Fig. 2 C and Fig. 3 E). 
As Foxa genes have never been implicated in hematopoiesis, 
we decided to explore Foxa3’s putative role in HSCs further 
by examining Foxa3−/− mice. Although Foxa3 is selectively 
expressed by HSCs in BM (Fig.  6  A), Foxa3−/− mice dis-
play normal PB counts and BM HSPC frequencies (Fig. 6, B 
and C). Foxa3−/− HSCs generated fewer CFU than Foxa3+/+ 
HSCs, suggesting a loss of functional HSCs, which could re-
sult from fewer absolute numbers of functional HSCs or a 
failure of HSC activation in culture (Fig. 6 D). Interestingly, 
Foxa3−/− LSK cells showed no loss of CFU potential relative 
to Foxa3+/+ LSK cells (unpublished data). As LSK cells are a 
mix of HSCs and progenitors, these data suggest that progen-
itors downstream of Foxa3−/− HSCs retain CFU potential.
CD45.2+ Foxa3−/− or Foxa3+/+ whole BM (WBM) was 
transplanted with an equal amount of CD45.1+ WBM into 
ablated CD45.1+/CD45.2+ recipients (Fig. 6, E and F). A sig-
nificant loss in CD45.2+ PB reconstitution was apparent in 
Foxa3−/− recipients relative to Foxa3+/+ recipients 20 wk after 
transplant (Fig. 6 F). There was no obvious skewing in the 
reconstitution of specific PB lineages in Foxa3−/− recipients 
(unpublished data). Although Foxa3−/− cells contributed less 
than Foxa3+/+ cells to recipient LSK, HSC, and MPP com-
partments (Fig.  6  G), Foxa3−/− chimerism in downstream 
progenitor compartments was unperturbed (unpublished 
data). When CD45.2+ WBM from primary recipients was 
transplanted into secondary recipients, Foxa3−/− WBM dis-
played an even more pronounced repopulating defect than in 
primary transplants (Fig. 6, E and F), suggesting that Foxa3−/− 
HSCs do not self-renew efficiently. Finally, Foxa3−/− WBM 
contained significantly fewer repopulating HSCs, relative to 
control, when transplanted at limiting dilutions (Fig.  6  H 
and Table S3; P = 0.0046).
In sum, Foxa3−/− HSCs are defective in CFU potential, 
primary and secondary in vivo repopulation, and the ability to 
efficiently contribute to the most primitive HSPC WBM com-
partments (HSC and MPP). These data suggest that Foxa3−/− 
BM contains fewer repopulating cells than Foxa3+/+ marrow 
and that self-renewal may be compromised in Foxa3−/− HSCs.
FOXA3-binding motifs are enriched in LT-HSC enhancers 
and target proliferative and stress pathways
To begin to understand how Foxa3 regulates HSC function, 
we asked whether the FOXA3 binding motif is significantly 
enriched in active and/or poised enhancers in long-term 
HSCs (LT-HSCs) and progeny (Lara-Astiaso et al., 2014). We 
found the FOXA3-binding motif enriched in enhancers ac-
tive in LT-HSCs but poised in downstream populations (Table 
S4), suggesting that Foxa3 likely functions at the level of the 
LT-HSCs, which agrees with our finding that Foxa3 is most 
highly expressed in HSCs (Fig.  6 A). These enhancers were 
not enriched for any other known transcription factor bind-
ing motifs, suggesting that Foxa3 either acts alone at these sites 
or cooperates with regulators whose motifs have not yet been 
defined (unpublished data). We next used IM-PET (Integrated 
Method for Predicting Enhancer Targets) to identify the pro-
moters likely targeted by these FOXA3-binding motif+ en-
hancers (Table S5; He et al., 2014). The resulting gene set was 
expressed higher than the rest of the genes in our microarray 
data (Foxa3+/+ HSC versus Foxa3−/− HSC), confirming reg-
ulation of these genes by Foxa3 in LT-HSCs (Fig.  7 A and 
Table S6). Gene Ontology (GO) enrichment analysis (Ash-
burner et al., 2000) of this gene set yielded terms including 
cell cycle (mitotic cell cycle and DNA replication), metabolism 
(nucleic acid biosynthesis and peptidyl-asparagine modifica-
tion), and stress (ER overload response, response to ER stress, 
ER-nuclear signaling pathway) as putative regulated processes 
(Table S7). Ingenuity Pathway analysis yielded multiple path-
ways that matched our gene set because of a common signature 
that included: Myc, Fos, Stat5a, PIK3CA, Nras, Grb2, PIK3CG, 
SOS1, and Stat3 (Table S8). These are molecules commonly 
found downstream of growth and cytokine receptors that in-
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terface with survival, cell cycle, and metabolic signaling. Un-
folded Protein Response and Endoplasmic Reticulum Stress 
Pathways also matched to our dataset. Top Predicted Regula-
tors included Myc, TP53, and TGFβ (Table S8). Finally, GSEA 
analysis also returned categories indicative of perturbed stress, 
signaling, and metabolic pathways (e.g., apoptosis by doxyru-
Figure 6. Foxa3 is dispensable for native hematopoiesis but required for HSC repopulating potential. (A) qRT-PCR of Foxa3 transcript. (B) PB 
counts of Foxa3+/+, Foxa3−/+, and Foxa3−/− littermates. (C) Absolute number of HSPCs in one femur + one tibia + one pelvis of 6–10-wk-old Foxa3−/− (n = 
5), Foxa3−/+ (n = 6), and Foxa3+/+ (n = 2) littermates. In B and C, each circle represents an independent mouse. (D) CFU activity of 150 Foxa3−/− (n = 5) or 
Foxa3+/+ (n = 5) HSCs. Error bars = SD. P = 6.2 × 10−6. (E) Schematic showing Foxa3−/− or Foxa3+/+ HSC strategies. (F) For first degree transplants, CD45.2+ 
Foxa3−/− or Foxa3+/+ WBM was transplanted with CD45.1+ WBM into ablated CD45.1+/CD45.2+ recipients in a 1:1 ratio. Percentage of CD45.2+ recipient PB 
at 20 wk after transplant is shown (*, P = 0.03). For 2° transplants, CD45.2+ WBM was isolated from 1° recipients 16 wk after transplant and transplanted 
into ablated CD45.1+/CD45.2+ mice. %CD45.2+ recipient PB is shown 16 wk after transplant for 2° transplant recipients (***, P = 0.0001). Each circle is an 
independently transplanted mouse. (G) The LSK, HSC, and MPP compartments of 1° recipients of CD45.2+ Foxa3−/− (n = 12) or Foxa3+/+ (n = 11) cells were 
examined >16 wk after transplant for the absolute number of CD45.2+ cells (shown as number of cells/one femur + one tibia + one pelvis). Each circle is 
an independent mouse. P = 0.02, 0.08, and 0.04, respectively. (H) 15,000, 30,000, 50,000, 100,000, or 200,000 CD45.2+ Foxa3−/− or Foxa3+/+ WBM cells were 
transplanted with CD45.1+ WBM into CD45.1+/CD45.2+ recipients. Recipients were scored as repopulated if their CD45.2+ PB chimerism was >1% in the T 
cell, B cell, and myeloid cell lineages 10–16 wk after transplant (data are the pooled results of two independently performed limiting dilution transplants). 
Each circle is an individual recipient (black circles label engrafted mice and red circles label nonengrafted mice). The number of mice engrafted/number of 
mice transplanted at each cell dose is shown. Significantly fewer repopulating HSCs were detected in Foxa3−/− WBM than Foxa3+/+ WBM (P = 0.0046). χ2 
analysis revealed a fit to the limiting dilution model (Table S3). These analyses were performed using L-Calc.
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bicin, up in CML, biopolymer metabolic process; Table S9). 
Cumulatively, these analyses implicate Foxa3 in the regulation 
of HSC metabolic and proliferative stress. To explore this fur-
ther, CD45.2+ HSCs (i.e., LSK CD150+CD48− cells) were iso-
lated from recipients of CD45.2+ Foxa3+/+ or Foxa3−/− WBM 
>8 mo after transplant and examined by staining with 2′,7′- 
dichlorofluorescin diacetate (DCF DA) for reactive oxygen spe-
cies (ROS). Foxa3−/− HSCs displayed a 50% increase in ROS 
relative to Foxa3+/+ HSCs (P = 0.006; Fig. 7 B). Despite the in-
crease in basal ROS levels, Foxa3−/− HSCs were able to recover 
from induced ROS similar to control HSCs (Fig. 7 B). These 
data confirm bioinformatics predictions that Foxa3−/− HSCs 
are subject to elevated metabolic stress. Further work will be 
required to determine exactly how Foxa3 contributes to the 
control of ROS levels in HSCs.
In sum, Foxa3 is dispensable to the hematopoietic com-
partment during homeostasis (Fig. 6, B and C), yet critical for 
optimal HSC function after transplant (Fig. 6 F). Under these 
conditions, activation of pathways regulating proliferation and 
metabolism is key. Indeed, the Foxa3−/− repopulating pheno-
type is most dramatic when greater pressure to repopulate is 
placed on individual cells (e.g., in limiting dilution transplants 
and serial transplantation; Fig. 6 H) and Foxa3−/− HSCs dis-
play a significant increase in ROS, which is known to com-
promise HSC self-renewal, maintenance, and repopulating 
potential (Ito et al., 2006; Jang and Sharkis, 2007; Tothova et 
al., 2007; Taniguchi Ishikawa et al., 2012).
DIS CUS SION
Here, we report a transplant-based screen for novel regulators 
of HSPC engraftment. By minimizing the ex vivo culture of 
HSPCs before transplant (24–44 h), we focused our study on 
identifying regulators of HSPC repopulation. Our approach 
used multiple independent shRNAs targeting prioritized gene 
candidates. Each shRNA was functionally validated to mediate 
robust gene knockdown in primary LSK cells (Fig. 1 D). To 
ensure high resolution of hits from non-hits, we verified robust 
cell transduction for each experiment in our functional screen 
(Fig. 2 B). Further, each putative hit was validated by retesting, 
thereby minimizing the likelihood of false positives caused by 
off-target effects or viral integration. More than 1,300 mice 
were transplanted to complete this study. These variables com-
bined to yield a hit rate of 41.5% (17/41 genes tested), illus-
trating the robustness of our approach and the fidelity of the 
publically available bioinformatics resources from which our 
gene candidates were drawn (Chambers et al., 2007; Heng and 
Painter, 2008; McKinney-Freeman et al., 2012).
We identified 17 new functional regulators of LSK cell 
in vivo repopulating activity: 15 are required for optimal re-
population (Arhgef5, Cadps2, Crispld1, Emcn, Foxa3, Fstl1, 
Glis2, Gpr56, Myct1, Nbea, P2ry14, Smarca2, Sox4, Stat4, and 
Zfp521) and 2 are negative regulators (Armcx1 and Gprasp2). 
12 of these genes have never been implicated in HSPC bi-
ology, although 5 (e.g., P2ry14, Smarca2, Sox4, and Gpr56) 
have recently been shown to play an important role in leuke-
mia or HSCs (Zhang et al., 2013; Buscarlet et al., 2014; Cho 
et al., 2014; Solaimani Kartalaei et al., 2015). These studies 
confirm that our screen has identified genes relevant to HSC 
function. Prior screens of mouse and human HSPCs involved 
extensive culture (12–17 d) before transplant or followed the 
preservation of a stem cell phenotype or colony formation 
during culture (5 d to 10 wk; Ali et al., 2009; Deneault et 
al., 2009; Boitano et al., 2010; Hope et al., 2010), thus bias-
ing their read-out for genes involved in self-renewal or stem 
cell maintenance, two processes critical to HSC function and 
culture. By minimizing LSK cell culture before transplant, we 
reasoned that our screen would identify genes regulating not 
only self-renewal, which can enhance HSPC repopulation, 
but also distinct cellular processes critical to the long-term 
reconstitution of an ablated hematopoietic system that may 
Figure 7. Foxa3 protects HSCs from cel-
lular stress. (A) Genes predicted by IM-PET 
to be targets of FOXA3 binding motif+ LT-HSC 
enhancers (Table S5) are significantly more 
perturbed in expression among genes dif-
ferentially expressed between Foxa3−/− and 
Foxa3+/+ HSCs (Table S6). P = 2.6 × 10−29. (B) 
CD45.2+ LSK CD150+CD48− cells were isolated 
from first degree recipients of Foxa3+/+ (n = 6) 
and Foxa3−/− (n = 7) BM and then stained with 
DCF DA to assess endogenous ROS levels (left) 
or treated with TBHP before DCF DA staining 
to induce elevated ROS (right). Values repre-
sent the percentage of cells positive for DCF 
DA in Foxa3−/− cells relative to Foxa3+/+ cells 
(left) or the relative fold change of DCF DA+ 
cells in Foxa3−/− versus Foxa3+/+ CD45.2+ LSK 
CD150+CD48− after TBHP treatment (right). For 
the left graph, P = 0.001 (*). P-values were cal-
culated via exact Wilcoxon Mann-Whitney test.
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not have been as readily discernable in these prior studies 
(e.g., niche lodgement and retention, survival under stress, 
activation, and differentiation).
Prior studies also often focused on specific molecular 
processes (e.g. nuclear factors, polarity and asymmetric divi-
sion, and histone methylation). Our screen was unbiased in 
that our two criteria were (1) confirmation by qRT-PCR 
of high expression in LSK cells and (2) identification of 
effective shRNAs. This approach discovered hits involved 
in distinct cellular and molecular processes, some currently 
understudied in HSPCs. For example, multiple likely regu-
lators of vesicular trafficking and cell surface receptor turn-
over were identified as regulators of LSK cell repopulating 
activity (Nbea, Cadsps2, Armcx1, and Gprasp2; Cisternas et 
al., 2003; Abu-Helo and Simonin, 2010; Moser et al., 2010; 
Niesmann et al., 2011; Fig.  3). These genes may regulate 
stable HSPC–niche interactions or the transduction of key 
survival signals during hematopoietic stress. Indeed, changes 
in CFU activity, cell cycle, and apoptosis in LSK cells main-
tained ex vivo after knockdown of Nbea, Cadps2, or Gprasp2 
(Fig. 5), suggest regulation of intrinsic pathways controlling 
differentiation, survival, and/or proliferation by these genes.
Arhgef5, a Rho guanine nucleotide exchange factor, 
has been implicated in podosome formation (Kuroiwa et al., 
2011). Podosomes are important for cell adhesion and mi-
gration. Knockdown of Arhgef5 in LSK cells maintained ex 
vivo resulted in an accumulation of cells in G1, as well as a loss 
of total CFU formation (Fig. 5 A and B). Gpr56, previously 
implicated in neuronal migration, was recently shown to par-
ticipate in HSC development and adhesion. Gpr56−/− HSCs 
also display a repopulating defect, as seen in our study after 
gene knockdown (Saito et al., 2013; Singer et al., 2013; Rao 
et al., 2015; Solaimani Kartalaei et al., 2015). We also identi-
fied secreted molecules (Fstl1 and Crispld1). Fstl1 is a TGFβ 
and BMP antagonist, whereas Crispld1 is likely a protease that 
targets the extracellular matrix (Gibbs et al., 2008; Geng et al., 
2011). Knockdown of Fstl1 in LSK cells led to fewer CFUs 
and loss of the LSK cell surface phenotype, suggesting an in-
trinsic loss of HSPC potential (Fig. 5). These genes suggest 
that, to facilitate stable engraftment and in vivo repopulation, 
HSPCs may autonomously condition their niche and culture 
by countering inhibitory signaling pathways (e.g., TGFβ) and 
remodeling the extracellular matrix (Arhgef5 and Crispld1).
Although Myct1 has never been implicated in HSPC 
function, it is a c-Myc target that modulates HSC–niche in-
teractions via N-cadherin (Wilson et al., 2004). There are cur-
rently no primary articles on Zfp521, a Krueppel-type C2H2 
zinc finger gene family member and possible transcriptional 
repressor, given it contains a KRAB domain (Urrutia, 2003). 
Knockdown of this gene in LSK cells perturbed CFU forma-
tion, appeared to enhance survival ex vivo, and led to a dramatic 
loss of chimerism downstream of the HSC compartment in the 
BM of transplanted mice, suggesting that Zfp521 regulates the 
differentiation and survival of HSPCs (Fig. 5). Although several 
of our hits are known to be expressed by HSPCs or have been 
implicated in leukemogenesis, here we show them to be regu-
lators of HSPC repopulation (Emcn, Glis2, Sox4, and Smarca2; 
Matsubara et al., 2005; Gruber et al., 2012; Masetti et al., 2013; 
Zhang et al., 2013; Buscarlet et al., 2014; Ma et al., 2014). Fi-
nally, our hit, the purinergic receptor P2ry14, was very recently 
shown to be an essential regulator of stress hematopoiesis and 
HSC repopulation, further validating our screen (Cho et al., 
2014). Globally, the results of our screen support a model in 
which active cross talk between the BM niche and HSPCs is 
essential for stable hematopoietic repopulation after transplant. 
Thus, exogenous treatment of HSCs with Fstl1 and Crispld1 
may promote their stable engraftment. Indeed, it was recently 
reported that Fstl1, which is also expressed in cardiac epicar-
dium, promotes the regeneration of cardiomyocytes both in 
vivo and ex vivo (Wei et al., 2015). This remains to be tested in 
HSPCs. Each hit identified here is a window into the processes 
that regulate the in vivo repopulating activity of HSPCs and 
warrant further investigation.
Although homing is critical to HSPC engraftment, 
our screen was not technically designed to identify hom-
ing regulators: in our system, maximum gene knockdown 
occurs 48–72 h after transduction (Holmfeldt et al., 2013). 
Transduced Test cells are transplanted 24–44  h after trans-
duction, before full gene knockdown. Thus, further work 
is required to determine whether any of the hits identified 
here regulate HSC homing.
We identified Foxa3 as a novel regulator of HSPC re-
population (Fig. 2 C and Fig. 3 E). Foxa genes have never be-
fore been implicated in HSPC biology. We found that Foxa3 
is highly expressed by HSCs (Fig. 6 A) and, although Foxa3−/− 
mice display normal hematopoiesis (Fig. 6, B and C), Foxa3−/− 
HSCs are deficient in CFUs and primary and secondary in 
vivo repopulation (Fig. 6, D–F). Other genes are also known 
to be dispensable for homeostasis but are absolutely required 
for HSC function under pathophysiological conditions, such 
as hematopoietic stress (e.g., p21, β-catenin, FoxOs, Gadd45a, 
and Gab2; Cheng et al., 2000; Zhang et al., 2007; Zhao et al., 
2007; Chen et al., 2014). Indeed, P2ry14, also identified here, 
is not required for steady-state hematopoiesis but is essential 
for HSC function after stress and injury (Cho et al., 2014). 
Thus, mechanisms that preserve the hematopoietic compart-
ment during stress (e.g., after transplantation) are often not 
required for homeostasis, and Foxa3 appears to be a newly 
discovered regulator of these processes. Indeed, genes targeted 
by active LT-HSC enhancers containing FOXA3-binding 
motifs were enriched for pathways controlling cell cycle, me-
tabolism, and stress, and Foxa3−/− HSCs display a significant 
increase in ROS content (Fig.  7 B and Tables S4 and S7–
S9). Increased ROS levels are known to compromise HSC 
self-renewal, quiescence, and repopulating potential (Ito et al., 
2006; Jang and Sharkis, 2007; Tothova et al., 2007; Taniguchi 
Ishikawa et al., 2012). Foxa3−/− HSC’s failure to efficiently 
repopulate ablated mice was most pronounced when limiting 
cell numbers were transplanted and after serial transplantation 
(Fig. 6 H). These are both scenarios in which the pressure on 
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individual repopulating cells to expand and differentiate is ex-
treme. In contrast, during homeostasis, when the pressure on 
individual cells to maintain steady-state hematopoiesis is low, 
Foxa3 is dispensable. Thus, in the absence of Foxa3, HSPCs 
fail to respond efficiently to hematologic stress.
HSPC in vivo repopulating activity is complex, requir-
ing the orchestration of many molecular and cellular pro-
cesses. This is evident by the disparate putative functions of 
the molecules identified in our screen. There is a burgeon-
ing interest in better understanding the regulation of stable 
HSPC engraftment, as manipulating this process represents 
a promising strategy for improving the efficiency of HSCT. 
Our study represents a valuable resource that will catalyze 
investigation into novel cellular mechanisms that may control 
this process. The better we understand the full scope of the 
cellular mechanisms that regulate stable HSPC engraftment, 
the better equipped we will be to develop novel therapies 
to improve HSCT outcomes.
MAT ERI ALS AND MET HODS
Mice. C57BL/6J and C57BL/6.SJL-PtprcaPep3b/BoyJ mice 
were acquired from The Jackson Laboratory and housed in a 
pathogen-free facility. All animal experiments were performed 
according to procedures approved by the St. Jude Children’s 
Research Hospital Institutional Animal Care and Use Com-
mittee. C57BL/6 Foxa3−/− mice were a gift from the laboratory 
of K. Kaestner (University of Pennsylvania, Philadelphia, PA).
Genotyping. PCRs were performed using GoTaq DNA Poly-
merase (Promega) and performed as indicated by the manu-
facturer. PCR conditions: 95°C, 2 min; (95°C, 30 min; 60°C, 
30 min; 72°C, 30 min) × 35; 72°C, 10 min. Primers: Foxa3 
F2 (5′-ACA TGA CCT TGA ACC CAC TC-3′), Foxa3 R1 (5′-
TAG TAC GGG AAG AGG TCC AT-3′), Foxa3 LacZ3 (5′-
AAT GTG AGC GAG TAA CAA CC-3′). WT PCR, Foxa3 F2+ 
Foxa3 R1; WT band, 349 bp. KO PCR, Foxa3 F2+ Foxa2 
LacZ3; Knock-out band, 648 bp. qRT-PCR total RNA iso-
lated from 70,000 LSK cells (RNeasy Micro kit; QIA GEN) 
was reversed transcribed into cDNA (High Capacity cDNA 
Reverse Transcriptional kit with RNase Inhibitor; Invitro-
gen). qRT-PCR was performed using Fast SYBR Green 
Master Mix (Applied Biosystems) on an ABI StepOnePlus 
thermal cycler (Applied Biosystems) according to the manu-
facturer’s instructions. PCR program: 95°C for 20 min; (95°C 
for 1 min and 60°C for 20 min) × 40; (Melt curve) 95°C for 
15 min; 60°C for 15 min; and 95°C for 15 min. Tbp expres-
sion levels were used to compensate for differences in cDNA 
input. ΔΔCt method was applied to calculate changes in gene 
expression. Primers were used at 0.4 µM. Primer sequences 
are listed in Table S1.
shRNAs. shRNAs were designed as previously described 
(Table S2; Fellmann et al., 2011; Holmfeldt et al., 2013). Gene 
knockdown efficiency in LSK cells was quantified by qRT-
PCR and normalized to transduction frequency (Table S2).
Lentiviral production. Vesicular stomatitis virus glycoprotein–
pseudotyped lentivirus was prepared as previously described 
via a four plasmid system (Transfer vector-, Gag/Pol-, Rev/
Tat-, and vesicular stomatitis virus glycoprotein envelope 
plasmid) by co-transfection of 293T cells using TransIT 293 
(Mirus; Holmfeldt et al., 2013). Viral supernatant was col-
lected 48 h later, cleared, and stored at −80°C. Viral prepara-
tions were titered on 293T cells.
LSK cell culture and transduction. LSK cells were isolated 
from 6–10-wk-old murine BM and transduced with lentivi-
rus as previously described (Holmfeldt et al., 2013). In brief, 
nontissue culture 96-well plates were coated with Retronec-
tin (TaKaRA Bio) according to the manufacturer’s instruc-
tions. Lentiviral particles corresponding to a multiplicity of 
infection (MOI) of 25 were spin loaded onto the plates for 
1 h at 1,000 g at room temperature. Wells were washed with 
PBS, followed by the addition of 15,000 freshly isolated LSK 
cells resuspended in 200  µl serum-free expansion medium 
(STE MCE LL Technologies) with 10 ng/ml recombinant 
murine (RM) stem cell factor (SCF), 20 ng/ml RM throm-
bopoietin (Tpo), 20 ng/ml RM insulin-like growth factor 2 
(IGF-2; PeproTech), 10 ng/ml recombinant human (RH) fi-
broblast growth factor 1 (FGF-1; R&D Systems), and 5 µg/ml 
protamine sulfate (Sigma-Aldrich). Cells were incubated 
overnight at 37°C. To collect cells for transplantation the next 
morning, media was slowly removed and cells were washed 
and resuspended in PBS + 1.5% FCS.
To compare the transduction efficiency of LSK cells ver-
sus LSK CD150+CD48− cells, these cells were isolated in par-
allel as previously described (Holmfeldt et al., 2013). 2,500 cells 
were transduced on graded concentrations of indicated viruses 
in retronectin-coated 96-well plates as described above. Trans-
duction frequencies were analyzed 4 d after transduction using 
flow cytometry. To assess any nonspecific effect of shRNAs on 
the viability of primitive hematopoietic cells, LSK cells trans-
duced with lentivirus were cultured for 2 wk in serum-free 
expansion medium (STE MCE LL Technologies) with 10 ng/
ml RM-SCF, 20 ng/ml RM thrombopoietin (Tpo), 20 ng/ml 
RM IGF-2 (PeproTech), 10 ng/ml RH-FGF-1 (R&D Sys-
tems), and 10 μg/ml heparin (Sigma-Aldrich). The persistence 
of mCherry+ cells was monitored using an LSR Fortessa (BD) 
and FlowJo version 9.4.11 (Tree Star).
BM transplants. Recipients were treated with 11 Gy of ion-
izing radiation in split doses of 5.5 Gy. For the functional 
screen, 5,000 CD45.2+ Test LSK cells were injected 24  h 
after transduction with 5,000 mock-transduced CD45.1+ 
Competitor LSK cells into recipients by tail vein. For retest-
ing of hits, 5,000 CD45.2+ Test mCherry+/LSK cells were 
isolated by FACS 44 h after transduction and injected with 
5,000 mock-transduced and mock-sorted CD45.1+ Com-
petitor LSK cells by tail vein. For 1:4 Test versus Compet-
itor transplants, 2,000 CD45.2+ Test mCherry+/LSK cells 
were isolated by FACS 44  h after transduction and trans-
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planted with 8,000 mock-transduced and mock-sorted 
CD45.1+ competitor LSK cells.
For investigating Foxa3, 4 × 105 CD45.2+ Foxa3+/+ or 
Foxa3−/− WBM cells were injected with 4 × 105 CD45.1+ 
WBM cells into lethally irradiated CD45.1+/CD45.2+ recip-
ients by tail vein. For secondary transplants, 4 × 105 CD45.2+ 
WBM cells sorted from primary recipients of Foxa3+/+ or 
Foxa3−/− WBM cells were transplanted with 4 × 105 CD45.1+ 
WBM WT competitor cells into lethally irradiated CD45.1+/
CD45.2+ recipients. For limiting dilution transplants, 15,000, 
30,000, 50,000, 100,000, or 200,000 CD45.2+ Foxa3+/+ or 
Foxa3−/− WBM cells were injected with 2 × 105 CD45.1+ 
WBM cells into lethally irradiated CD45.1+/CD45.2+ recip-
ients by tail vein in two independent experiments. Engraft-
ment was defined as >1% CD45.2 chimerism in the T cell, 
B cell, and myeloid lineages of recipient PB 10–16 wk after 
transplant. l-Calc (STE MCE LL Technologies) was used to 
analyze the results of the limiting dilution transplants.
Antibodies for WBM and PB analysis. All antibodies used in this 
study for the analysis of WBM and PB cell populations by flow 
cytometry are as previously described (Holmfeldt et al., 2013).
Analysis of PB. PB was collected from the retro-orbital 
plexus in heparinized capillary tubes and lysed in red blood 
cell lysis buffer (Sigma-Aldrich). Cells were stained with the 
following antibodies: CD45.1-FITC, CD45.2-APC, (B220, 
Gr1, Cd11b)-PerCPCy5.5, and (B220, CD4, CD8)-PECy7 
(BD), followed by flow cytometry analysis using an LSR 
Fortessa and data analysis using FlowJo version 9.4.11.
CFU assays. For analysis of CFU potential of LSK cells after 
knockdown of screen hits, LSK cells were transduced overnight 
with control or gene-specific shRNAs, and then cultured at 
15,000 cells/well in non-tissue culture–treated 96-well plates 
for 5–6 d in serum-free expansion medium (STE MCE LL 
Technologies) with 10 ng/ml RM SCF, 20 ng/ml RM Tpo, 20 
ng/ml RM IGF-2 (PeproTech), 10 ng/ml RH FGF-1 (R&D 
Systems), and 10 µg/ml heparin (Sigma-Aldrich). 500 
mCherry+ LSK cells were then isolated by FACS and plated in 
M3434 methylcellulose (STE MCE LL Technologies). For CFU 
analysis of Foxa3+/+ or Foxa3−/− HSCs, 150 HSCs (LSK 
CD150+CD48−) were isolated by FACS from WBM, and then 
plated in M3434. Colonies were analyzed 10 d after plating.
Cell cycle analysis of shRNA-transduced LSK cells. LSK cells 
were transduced overnight with control or gene-specific 
shRNAs and then cultured at 15,000 cells/well in nontis-
sue culture treated 96-well plates for 5–6 d in serum-free 
expansion medium (STE MCE LL Technologies) with 10 
ng/ml RM SCF, 20 ng/ml RM Tpo, 20 ng/ml RM IGF-2 
(PeproTech), 10 ng/ml RH FGF-1 (R&D Systems), and 10 
µg/ml heparin (Sigma-Aldrich). mCherry+ LSK cells were 
then collected by FACS and stained with the following anti-
bodies: (B220, CD3, CD4, CD8, CD19, Gr-1, and Ter119)-
PerCP, Sca-1-PerCP-Cy5.5, and c-Kit-APC-780. Cells 
were then fixed using the Cytofix/Cytoperm kit (BD), fol-
lowed by staining for Ki67-FITC (Clone SolA15; eBiosci-
ence) and DAPI. Cells were analyzed via an LSR Fortessa 
and FlowJo version 9.4.11.
Apoptosis analysis of shRNA-transduced LSK cells. LSK cells 
were transduced overnight with control or gene-specific shR-
NAs and then cultured at 15,000 cells/well in non-tissue cul-
ture–treated 96-well plates for 5–6 d in serum-free expansion 
medium (STE MCE LL Technologies) with 10 ng/ml RM 
SCF, 20 ng/ml RM Tpo, 20 ng/ml RM IGF-2 (PeproTech), 
10 ng/ml RH FGF-1 (R&D Systems), and 10 µg/ml hepa-
rin (Sigma-Aldrich). Cells were collected 5–6 d after plating 
and stained with the following antibodies: (B220, CD3, CD4, 
CD8, CD19, Gr-1, and Ter119)-PerCP, Sca-1-PerCP-Cy5.5, 
and c-Kit-APC-780. After staining for surface antigens, cells 
were labeled with Annexin V-FITC (BD) and DAPI, and then 
analyzed using an LSR Fortessa and FlowJo version 9.4.11.
Analysis of total blood counts in Foxa3 mice. PB was har-
vested from the retro-orbital plexus in heparinized capillary 
tubes and analyzed on a Forcyte instrument (Oxford Scientific).
Analysis of HSPCs in transplant recipients and Foxa3 mice. 
Tibias, femurs, and pelvic bones were removed from mice 
and BM isolated by crushing. BM was then lysed in red blood 
cell lysis buffer (Sigma-Aldrich). Donor-derived HSCs (LSK 
CD150+CD48−), MPPs (LSK Flt3L+), common myeloid 
progenitors (CMPs; Lineage−c-Kit+Sca-1−FcRlowCD34+), 
common lymphoid progenitors (CLPs; Lineage−c-KitLow 
Sca-1LowIL7R+), granulocyte-myeloid progenitors (GMPs; Lin-
eage−c-Kit+Sca-1−FcRhighCD34+), and megakaryocyte-eryth-
roid progenitors (MEPs; Lineage−c-Kit+Sca-1−FcR−CD34−) 
were visualized in transplant recipients by staining with the 
following antibodies: HSC ([B220, CD3, CD4, CD8, CD19, 
Gr-1, Ter119]-PerCP, Sca-1-PerCP-Cy5.5, c-Kit-APC-780, 
CD150-PE-Cy7, CD48-Alexa Fluor 700, CD45.1-FITC, 
and CD45.2-v500); CMP/GMP/MEP ([B220, CD3, CD4, 
CD8, CD19, Gr-1, Ter119]-PerCP, Sca-1-PerCP-Cy5.5, c-Kit-
APC-780, FcR II/III-Alexa Fluor 700, CD34-FITC, CD45.1-
APC, and CD45.2-v500); and CLP/MPP (B220, CD3, CD4, 
CD8, CD19, Gr-1, Ter119)-PerCP, Sca-1-PerCP-Cy5.5, 
c-Kit-APC-780, IL-7R-PE-Cy7, Flt3-APC, CD45.1-FITC, 
and CD45.2-v500. HSPCs were visualized in Foxa3−/− and 
Foxa3+/+ mice as described above with the exclusion of CD45.1 
and CD45.2. Cells were then analyzed using an LSR Fortessa 
and data analysis was done using FlowJo version 9.4.11. DAPI 
(Sigma-Aldrich) was used for dead cell exclusion.
Analysis of FOXA3-binding motifs in HSC enhancers and gene 
targets. Active and poised enhancers in LT-HSC, ST-HSC, MPP, 
and GMP were obtained from the enhancer compendium gen-
erated by Lara-Astiaso et al. (2014). These enhancers were iden-
tified based on their histone modification signatures. For FOXA3 
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motif analysis, we downloaded the position weight matrix of 
FOXA3 motif from the Cis-BP database (Weirauch et al., 2014). 
We used FIMO to scan the enhancer sequences for the occur-
rence of FOXA3 binding motifs with a p-value threshold of 10−5 
(Grant et al., 2011). To predict the target genes of FOXA3 bind-
ing motif+ enhancers, we used the integrated method for pre-
dicting enhancer targets (IM-PET) software (He et al., 2014), 
which predicts enhancer-promoter interactions by integrating 
transcriptomic, epigenomic, and genomic sequence information. 
Histone modification and RNA-Seq data acquired by IM-PET 
were from (Cabezas-Wallscheid et al., 2014; Lara-Astiaso et al., 
2014). The predicted targets of FOXA3-binding motif+ en-
hancers in LT-HSCs were extracted for GSEA analysis.
Foxa3 microarray. Total RNA was isolated from 10,000 
Foxa3+/+ or Foxa3−/− HSCs using the RNeasy Micro kit 
(QIA GEN). RNA was amplified by the NuGEN Ovation 
Pico WTA V2 system and labeled using the NuGEN Encore 
Biotin Module (NuGen). Labeled targets were hybridized on 
the HT MG-430 PM plate array and processed using the 
GeneTitan system (Affymetrix). Array data were quantile 
normalized and robust multi-array average summarized in 
Genomics Suite 6.6 (Partek). The complete dataset is depos-
ited in the Gene Expression Omnibus (GSE63830.).
Analysis of ROS content in Foxa3+/+ and Foxa3−/− HSCs. 
Foxa3+/+ and Foxa3−/− WBM was isolated, magnetically 
enriched for c-Kit+ cells, and then stained with Sca-1-
PerCP-Cy5.5, c-Kit-APC-780, CD150-PE-Cy7, and 
CD48-Alexa Fluor 700. Cells were then treated with vehi-
cle or 500 µM tert-butyl Hydrogen Peroxide (TBHP). 3 h 
after treatment, cells were stained with 5 µM DCF DA for 
30 min on ice and then analyzed via an LSR Fortessa and 
FlowJo version 9.4.11. The peak excitation wavelength for 
oxidized DCF was 488 nm and emission was 525 nm.
Statistics. Statistical significance for comparisons between 
two groups was assessed using two sample t tests or exact 
Wilcoxon Mann-Whitney tests, depending on the normal-
ity test based on the Shapiro-Wilk test. Measurements for 
each gene were normalized to their respective control and a 
one sample t test was performed to assess if the mean of the 
normalized measurements is equal to one. All these analyses 
were performed in SAS version 9.3. For limiting dilution 
analysis (LDA), parameters were estimated using a general-
ized linear model with a complementary log-log link. χ2 
(Pearson and Deviance) were used to assess the goodness-
of-fit to the LDA model. Differences in the frequency of 
HSCs between Foxa3+/+ and Foxa3−/− mice were assessed 
by relying on the asymptotic normality of the maximum 
likelihood estimation. LDA were performed using l-Calc 
(STE MCE LL Technologies). All the reported p-values are 
two-sided and considered statistically significant if P < 0.05, 
although P < 0.1 is also noted in some instances as 
marginally significant.
Online supplemental material. Fig. S1 presents gating flow 
cytometry gating strategies for the ex vivo analysis of cell cycle, 
cell surface phenotype, and apoptosis. Table S1 presents qRT-
PCR primer sequences. Table S2 presents a summary of genes 
tested in functional screen and corresponding shRNA 
sequences. Table S3 presents Foxa3−/− and Foxa3+/+ WBM 
predicted repopulating cell frequency, along with their 95% 
confidence interval based on limiting dilution transplant. Table 
S4 presents FOXA3 binding motif enrichment in enhancers 
active in LT-HSCs and poised in other HSPC compartments 
(Lara-Astiaso et al., 2014). Table S5 presents predicted gene 
targets of Foxa3 motif+ active LT-HSC enhancers. Table S6 
presents microarray results of Foxa3−/− HSCs versus Foxa3+/+ 
HSCs. Table S7 presents GO analysis results. Table S8 presents 
Ingenuity pathway analysis. Table S9 presents GSEA analysis 
results. Online supplemental material is available at http ://
www .jem .org /cgi /content /full /jem .20150806 /DC1.
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